August 2015

New Product - Entyvio

Entyvio (vedolizumab (rch)) is a humanised IgG1 monoclonal antibody that binds to the human α4β₇ integrin and is produced in Chinese hamster ovary cells. Entyvio is indicated in the treatment of adult patients with moderate to severe ulcerative colitis who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. It is also indicated in the treatment of adult patients with moderate to severe Crohn’s disease who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a TNFα antagonist. Entyvio is contraindicated with active severe infections such as sepsis, tuberculosis, opportunistic infections, and serious abscesses. Entyvio is available as a powder for injection in a single use vial containing 300 mg of vedolizumab.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au